Avanos Medical, Inc. (NYSE:AVNS) Shares Sold by Nuveen Asset Management LLC

Nuveen Asset Management LLC decreased its holdings in Avanos Medical, Inc. (NYSE:AVNS – Get Rating) by 31.5% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 408,078 shares of the company’s stock after selling 188,057 shares during the period. Nuveen Asset Management LLC owned approximately 0.88% of Avanos Medical worth $8,888,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the business. Envestnet Asset Management Inc. increased its holdings in shares of Avanos Medical by 7.6% during the 3rd quarter. Envestnet Asset Management Inc. now owns 61,663 shares of the company’s stock worth $1,343,000 after buying an additional 4,358 shares during the last quarter. Credit Suisse AG increased its holdings in shares of Avanos Medical by 1.0% during the 3rd quarter. Credit Suisse AG now owns 44,203 shares of the company’s stock worth $964,000 after buying an additional 458 shares during the last quarter. Heartland Advisors Inc. increased its holdings in shares of Avanos Medical by 16.8% during the 3rd quarter. Heartland Advisors Inc. now owns 461,714 shares of the company’s stock worth $10,056,000 after buying an additional 66,573 shares during the last quarter. Hillsdale Investment Management Inc. increased its holdings in shares of Avanos Medical by 7.7% during the 3rd quarter. Hillsdale Investment Management Inc. now owns 182,400 shares of the company’s stock worth $3,973,000 after buying an additional 13,000 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in shares of Avanos Medical by 7.1% during the 3rd quarter. Dimensional Fund Advisors LP now owns 2,827,807 shares of the company’s stock worth $61,590,000 after buying an additional 188,035 shares during the last quarter. Institutional investors and hedge funds own 92.08% of the company’s stock.

Avanos Medical Stock Performance

NYSE:AVNS opened at $27.22 on Friday. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.67 and a current ratio of 2.69. The stock has a market capitalization of $1.27 billion, a P/E ratio of 25.92 and a beta of 0.93. The company has a 50 day moving average price of $29.20 and a 200 day moving average price of $26.03. Avanos Medical, Inc. has a fifty-two week low of $19.32 and a fifty-two week high of $34.83.

Avanos Medical (NYSE:AVNS – Get Rating) last posted its quarterly earnings data on Tuesday, February 21st. The company reported $0.60 earnings per share for the quarter, topping analysts’ consensus estimates of $0.48 by $0.12. Avanos Medical had a net margin of 6.07% and a return on equity of 6.13%. The firm had revenue of $217.50 million during the quarter, compared to analysts’ expectations of $217.30 million. During the same quarter last year, the company posted $0.46 EPS. The firm’s quarterly revenue was up 12.5% on a year-over-year basis. Equities research analysts forecast that Avanos Medical, Inc. will post 1.7 EPS for the current year.

Analyst Ratings Changes

AVNS has been the subject of a number of recent analyst reports. Morgan Stanley raised their price target on shares of Avanos Medical from $26.00 to $28.00 and gave the stock an “underweight” rating in a report on Wednesday, February 22nd. StockNews.com raised shares of Avanos Medical from a “buy” rating to a “strong-buy” rating in a research report on Wednesday.

Avanos Medical Company Profile

(Get Rating)

Avanos Medical, Inc operates as a medical technology company. It focuses on delivering clinically medical device solutions to improve patients’ quality of life. The firm’s portfolio of product offerings focuses on respiratory and digestive health, along with surgical and interventional pain management to improve patient outcomes and reduce the cost of care.